Trouble Viewing This Email: Click Here

October 24, 2023


Biden-Harris Administration Designates 31 Tech Hubs Across America Including Maryland & Virginia

As part of the President’s Investing in America agenda, the U.S. Department of Commerce identified regional centers primed for technological innovation and job creation.

WASHINGTON, DC — The Biden-Harris administration, through the U.S. Department of Commerce’s Economic Development Administration (EDA), today announced the designation of 31 Tech Hubs in regions across the country. This is the first phase of the new Tech Hubs program, which is an economic development initiative designed to drive regional innovation and job creation by strengthening a region’s capacity to manufacture, commercialize, and deploy technology that will advance American competitiveness.  The program invests directly in burgeoning, high-potential U.S. regions and aims to transform them into globally competitive innovation centers.

Read More

TEDCO Announces Investment into Sisu Global Health (A BHI Portfolio Company) 

Maryland-based, woman-owned biotech company providing hospitals with an autotransfusion device to address the global blood shortage

COLUMBIA, Md. (October 23, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent Inclusion Fund investment of $100,000 into Sisu Global Health, a company that is providing hospitals with an autotransfusion device to replace or augment donor blood in emergency situations.

Sisu Global Health, based in Baltimore, Md., has created an autotransfusion device, Hemafuse; the device provides surgical patients access to fresh, whole blood by capturing it from internal bleeding and giving it back to them immediately in the same surgery. The patented Hemafuse System can operate anywhere there is a surgeon (regardless of infrastructure), making it well suited for military and emerging markets, with applications in the U.S., Sisu Global is bringing Hemafuse to the global market after clinical success in Ghana, Kenya, Tanzania and Ukraine.

Read More

Baltimore's MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours

Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects

MyMD was issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments

BALTIMORE--()--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced results from a preclinical study of its investigational cannabinoid Supera-CBD™, a novel, synthetic, non-toxic cannabidiol (CBD) analog. In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes, providing pain relief for up to five hours. Comparatively, traditional CBD had no effect on this type of pain in the same study.

Read More

BioTalk - Revolutionizing Autoimmune Medicine: MyMD Pharmaceuticals Innovative Therapies

Are you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations it could benefit. And that's not all. We also spotlight Supera-CBD, a novel synthetic cannabidiol with incredible potency and anti-inflammatory effects. How could this innovation change the landscape of chronic pain and anxiety management? Don't miss this episode of BioTalk with Rich Bendis as we embark on a journey into the future of autoimmune medicine with MyMD Pharmaceuticals. Tune in now and be part of the conversation.

Listen now via your favorite podcasting platform:

Click here to read the transcript.

Read More

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma

ROCKVILLE, Md.--()--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced safety and tolerability results from its phase 1 clinical trial evaluating ITI-3000, a plasmid DNA (pDNA) vaccine, targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV). ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.

Read More

FDA Clears Rise Therapeutics' IND Application to Initiate a Phase 1 Clinical Study

FDA Clears Rise Therapeutics' IND Application to Initiate a Phase 1 Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis

ROCKVILLE, Md., Oct. 19, 2023 /PRNewswire/ -- Rise Therapeutics a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics' second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform.

Read More

FDA Clears Rise Therapeutics' IND Application to Initiate a Phase 1 Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)-- Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs. Qnovia will work with UVA School of Medicine investigators Dr. Molly Hughes and Dr. Matthew Crawford to combine Qnovia’s RespiRxTM inhaled drug delivery platform and UVA’s proprietary portfolio of antimicrobial peptides to kill antibiotic-resistant and biodefense bacteria that can cause life-threatening infections. As a result of this agreement, Qnovia will add two new assets to its development pipeline: QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection for individuals exposed to the biodefense agent B. anthracis, the causative agent of anthrax.

Read More

IndoUSrare Announces Bridging RARE Summit to Combat Rare Diseases by Fostering Cross-Border Collaborations, Data Sharing, and Clinical Trials - Register Now

With an increasing number of U.S. biopharmaceutical firms feeling the financial constraints imposed by the Inflation Reduction Act (IRA) and subsequently shutting down or suspending their research programs in the rare disease domain, hundreds of millions of patients in both the U.S. and India face the grim prospect of not receiving a breakthrough treatment for their condition within their lifetimes. IndoUSrare, a US-based nonprofit committed to stanching rare diseases, launches the inaugural Bridging RARE conference to forge a path for affordable clinical innovation via strengthened Indo-US collaborations and more inclusive clinical trials for minimizing the devastating health consequences arising from this policy shift.

(HERNDON, Va.) October 10, 2023: Rare diseases, as defined by the World Health Organization (WHO), refer to some 10,867 medically significant conditions, each with a prevalence of one or less per 1,000 individuals. With only about 8% of them being treatable,1 rare diseases include congenital malformations, autoimmune disorders, lysosomal storage disorders, thalassemia, muscular dystrophies, and infrequent forms of cancer and infections. Despite substantial progress during the 40 years since the enactment of the Orphan Drug Act of 1983, which incentivized the U.S. private sector to develop 1,100 FDA-approved orphan treatments,2 the global thrust against rare diseases is on the verge of losing steam.


Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright  BioHealth Innovation 2023
All Rights Reserved.